April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Radioprotective Effects of a Cell-Permeable Redox Agent on Retinal Endothelial Cells
Author Affiliations & Notes
  • A. F. Thompson
    Ophthalmology and Visual Sciences, University of Wisconsin, Madison, Wisconsin
  • C. J. Lieven
    Ophthalmology and Visual Sciences, University of Wisconsin, Madison, Wisconsin
  • N. Sheibani
    Ophthalmology and Visual Sciences, University of Wisconsin, Madison, Wisconsin
  • L. A. Levin
    Ophthalmology and Visual Sciences, University of Wisconsin, Madison, Wisconsin
    Ophthalmology, University of Montreal, Montreal, Quebec, Canada
  • Footnotes
    Commercial Relationships  A.F. Thompson, None; C.J. Lieven, Cytodefense, E; N. Sheibani, Cytodefense, C; L.A. Levin, Wisconsin Alumni Research Foundation, P; Cytodefense, I; Cytodefense, E.
  • Footnotes
    Support  NIH R21EY017970 and P30EY016665, an unrestricted departmental grant from Research to Prevent Blindness, Inc, and a Wisconsin Alumni Research Foundation Lead Discovery Initiative Grant
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 1403. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A. F. Thompson, C. J. Lieven, N. Sheibani, L. A. Levin; Radioprotective Effects of a Cell-Permeable Redox Agent on Retinal Endothelial Cells. Invest. Ophthalmol. Vis. Sci. 2010;51(13):1403.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Radiation retinopathy and radiation optic neuropathy are common adverse effects of radiation treatment of ocular tumors. One of the mechanisms for neuroretinal radiation damage is injury to endothelial cells (Levin LA et al., Ophthalmology 107:370, 2000), possibly mediated by generation of reactive oxygen species. We hypothesized that a phosphine-borane complex which we had previously shown to be neuroprotective of retinal ganglion cells following axotomy (Schlieve CR et al., Exp Eye Res 83:1252, 2006) would protect retinal endothelial cells from radiation damage.

Methods: : Retinal endothelial cells (Su X et al., Mol Vis 9:171, 2003) were subjected to ionizing radiation from a 137Cs source, using single doses from 1 to 30 Gy. Experimental groups of cells were treated with bis(3-propionic acid methyl ester)phenylphosphine borane complex (PB1) at concentrations ranging from 100 pM to 100 uM 18 hours before, immediately preceding, or 18 hours after irradiation. Cell viability was assessed by staining live cells with calcein-AM 72 hours after irradiation. Cells were photographed and batch-analyzed using ImageJ.

Results: : Retinal endothelial cell viability was reduced to 56.1 ± 6.3% and 37.1 ± 3.5% of control following 10 and 30 Gy irradiation, respectively (p < 0.004 for both comparisons). Treatment with 10 nM or 100 nM PB1 18 hours before, immediately preceding, or 18 hours after 10 Gy irradiation significantly increased numbers of viable cells (p < 0.05). Treatment with 10 nM PB1 18 hours after 10 Gy irradiation showed the strongest protective effect (viable cells increased to 127.8 ± 20.3% of control, p = 0.005). Treatment with all PB1 concentrations tested between 100 pM and 100 µM at any of the three experimental time points significantly increased numbers of viable cells following 30 Gy irradiation (p < 0.05). 10 nM PB1 treatment immediately before irradiation was most protective against this highest 30 Gy radiation dose (viable cells increased to 101.1 ± 9.6% of control, p < 0.0001).

Conclusions: : The redox modulating agent PB1 has a radioprotective (administration before radiation) and radiomitigative (administration after radiation) effect in irraditated retinal endothelial cells. The mechanism may relate to interruption of oxidative signaling pathways for apoptosis induced by radiation.

Keywords: apoptosis/cell death • antioxidants • oxidation/oxidative or free radical damage 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×